CTOs on the Move


 
PathWell Health is a Medicare certified home healthcare agency that offers skilled nursing and therapy services to help patients maintain independence and quality of life in the comfort of their own homes.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

www.bauschhealth.com

Bausch Health Companies Inc. is a global company whose mission is to improve peoples lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.

Pyx Health

Pyx Health is leading the solution to Loneliness and Social Isolation through technology and human connection.

Health Republic Insurance

Health Republic Insurance of New York is a not-for-profit health insurance CO-OP (Consumer Operated and Oriented Plan) established under the Affordable Care Act to expand affordable healthcare options for all New Yorkers. Our high-quality plans are available to individuals and small groups, both on exchange and off, throughout the state. Since we opened our doors in October of 2013, we`ve enrolled over 145,000 members, making us the largest health insurance cooperative in the country and one of the fastest growing insurance companies in New York history. Our tremendous success is a testament to the way our values resonate with our members.

Biodex

Biodex Medical Systems, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Biodex Medical Systems, Inc. is based in Shirley, NY. You can find more information on Biodex Medical Systems, Inc. at www.biodex.com

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.